United States

Heat Biologics Inc (HTBX.OQ)

HTBX.OQ on NASDAQ Stock Exchange Capital Market

18 Oct 2017
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combinatio... (more)


Beta: 0.79
Market Cap(Mil.): $22.51
Shares Outstanding(Mil.): 35.79
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 89.64 16.86
EPS (TTM): -- -- --
ROI: -- 2.40 11.22
ROE: -- 3.29 15.09

BRIEF-Heat Biologics sets subscription price of $0.62/shr for its intended rights offering to certain existing security holders

* Says subscription price of $0.62 per share for its intended rights offering to certain of co's existing security holders - SEC filing​ Source text for Eikon: (http://bit.ly/2wZmeaM) Further company coverage:

Oct 16 2017

BRIEF-Heat Biologics been granted type C meeting with FDA

* Heat Biologics- ‍been granted type C meeting with FDA; to discuss registrational pathway for non-small cell lung cancer trial with HS-110 in combination with Bristol Myers' opdivo Source text: (http://bit.ly/2wY2UeW) Further company coverage:

Sep 12 2017

Earnings vs. Estimates